Poor
Mostly Unaligned
Patient Risk:
Medium
Summary
Most claims are not supported or contradicted by the provided FDA labeling excerpts (which cover indication/description/dosing, contraindications, warnings/adverse reactions headings, and limited population info). Multiple drug-identifying/molecular claims are unsupported because the label excerpt provided states the active ingredient as viloxazine, not trazodone. No label support is provided for pricing, coupons, prior authorization, or patent/cost discussion.
Category Scores
Accurate Statements
Qelbree is a branded medication.
Unsupported: the provided label excerpt does not state whether it is branded; however, labeling describes Qelbree as the drug product.
Unsupported Statements
A 30-day supply of Qelbree (200 mg) could cost over $2,000 without insurance.
No pricing/cost information is present in the supplied prescribing information excerpts.
Manufacturer coupons and patient assistance programs are available for Qelbree and may significantly reduce cost for eligible individuals.
No information about coupons, patient assistance, or affordability programs appears in the supplied labeling excerpts.
Insurance coverage for Qelbree varies by plan.
No payer/coverage guidance is included in the supplied labeling excerpts.
Some insurance providers may require prior authorization for Qelbree or have specific tier placements for the drug.
No prior authorization or formulary tier information is present in the supplied labeling excerpts.
Manufacturer-sponsored programs, such as the Qelbree Savings Card, can help eligible commercially insured patients pay as little as a $0 copay for their prescription.
No savings card, copay amount, or specific program details are included in the supplied labeling excerpts.
Patient assistance programs may offer further support for people who are uninsured or underinsured.
No patient assistance program content is included in the supplied labeling excerpts.
Several alternative medications are available for ADHD, including generics of older stimulant and non-stimulant medications.
The supplied labeling excerpts do not list alternative ADHD medications or generics.
Generics of older stimulant and non-stimulant medications generally have lower costs than newer branded drugs like Qelbree.
No cost comparisons between Qelbree and other medications are provided in the supplied labeling excerpts.
Qelbree's specific formulation and indication for ADHD may be covered by separate patents.
No patent or exclusivity information is provided in the supplied labeling excerpts.
Expiration of patents can open the door for generic competition, potentially leading to lower prices.
No discussion of patents, generic competition, or pricing impact is included in the supplied labeling excerpts.
Contradictions
High
AI Statement
The active ingredient of Qelbree is trazodone.
Label Reference
11 DESCRIPTION: Qelbree contains viloxazine (viloxazine hydrochloride).
Low
AI Statement
Trazodone is available as a generic.
Label Reference
11 DESCRIPTION does not support trazodone as the active ingredient of Qelbree; the supplied labeling excerpts provide no statements about trazodone generic availability.
Important Omissions
For any dosing-related or safety-related discussion (e.g., 200 mg 30-day supply), the label excerpt provides dosage recommendations but the AI claim about cost/dosing context does not align with any supported label dosing instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Incorrect identification of Qelbree's active ingredient (viloxazine vs trazodone) is potentially clinically significant; however, none of the claims provided contained direct prescribing instructions or contraindication/warning misapplication from the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Active ingredient misidentification (viloxazine described in labeling vs trazodone claimed). Most cost/coverage/coupon/patent claims are absent from the provided FDA label excerpts.
Suggested Improvement
Remove or correct unsupported/non-label claims (pricing, coupons, prior authorization, savings card details, patent/generic pricing rationale) and correct the active ingredient to viloxazine (viloxazine hydrochloride), consistent with the supplied label excerpt.